Understanding the genetic architecture of athletic performance is an important step in the
development of methods for talent identification in sport. Research concerned with …

Bevacizumab is the first antiangiogenic therapy proven to slow metastatic disease
progression in patients with cancer. Although it has changed clinical practice, some patients …

BACKGROUND Pre-eclampsia, small-for-gestational-age infants, preterm birth and
recurrent miscarriage complicate a significant number of pregnancies. The vascular …

Bevacizumab is a vascular endothelial growth factor-A-specific angiogenesis inhibitor
indicated as an adjunct to chemotherapy for the treatment of several types of cancer …

Purpose To identify genetic markers in the pharmacokinetic and pharmacodynamic
pathways of sunitinib that predispose for development of toxicities: thrombocytopenia …

Purpose Pazopanib, an oral angiogenesis inhibitor, is approved for the treatment of
advanced renal cell carcinoma (RCC). Response to pazopanib monotherapy varies …

Anti-angiogenic agents are biological drugs used for treatment of retinal neovascular
degenerative diseases. In this study, we aimed at in silico analysis of interaction of vascular …

Approximately 50% of patients with primary colorectal carcinoma develop liver metastases.
Understanding the genetic differences between primary colon cancer and their metastases …

The ability to perform aerobic or anaerobic exercise varies widely among individuals,
partially depending on their muscle-fiber composition. Variability in the proportion of skeletal …

INTRODUCTION: The pregnancy complications preeclampsia, gestational hypertension,
small for gestational age infants (SGA) and pre-term birth (PTB) affect approximately 21% of …